Highlights from the 2025 American Society of Clinical Oncology Annual meeting: head-and-neck cancers
Introduction Head and neck squamous cell carcinoma (HNSCC) represents a heterogenous group of diseases, and remains a major global health challenge, with survival rates for locally advanced disease showing limited improvement despite multimodal therapy strategies. The American Society of Clinical Oncology (ASCO) Annual Meeting is a premier global forum for presenting cutting-edge oncology research and […]
Molecularly targeted agents and tumor biology
Regarding the area of “Developmental Therapeutics Molecularly Targeted Agents and Tumor Biology,” the presentations selected were: – Abstract 3002 – Phase I study of iza-bren (BL-B01D1), an epidermal growth factor receptor × human epidermal growth factor receptor 3 (EGFR × HER3) bispecific antibody-drug conjugate (ADC), in patients (pts) with locally advanced or metastatic small cell […]
Highlights from the 2025 ASCO annual meeting: central nervous system
Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial Prior trials have demonstrated that stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) yields better outcomes than traditional whole brain radiotherapy (WBRT) in patients with 1-4 brain metastases, and that hippocampal avoidance WBRT (HA-WBRT) is superior to traditional […]
Breast cancer panel: summary of 5 key studies
At the Best of ASCO 2025 meeting hosted by the Portuguese Society of Oncology, five studies were presented in the Breast Cancer panel, all considered relevant to present clinical practice. One focused on early-stage breast cancer (NeoCARHP), while the remaining studies addressed advanced breast cancer (aBC), including two on luminal human epidermal growth factor receptor […]
Best of ASCO 2025 narrative review article – Skin cancer
DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM) – Final clinical results BRAF is one of the most commonly mutated oncogenes in melanoma1. Patients with BRAF-mutant MM can be treated either with targeted therapy (TT) or with combined immunotherapy (IO)2–4 such as nivolumab and ipilimumab5 both of which have […]
Best of ASCO 2025 – Survivorship
Introduction For the section Survivorship and Symptom Control at the Sociedade Portuguesa de Oncologia (SPO) Best of ASCO 2025 – Official Licensed Annual Meeting, we aimed to select abstracts answering tangible questions regarding the management of frequent challenges encountered by oncologists on their daily routine. Evidence has shown that the development of optimized supportive care […]
Testing positive after genetic testing for hereditary cancer: what’s next?
Introduction The growing integration of genetics into clinical oncology practice has led to an increase in the number of individuals (both cancer survivors and those without prior oncological diagnoses) identified with genetic variants associated with hereditary cancer. These individuals require a multidisciplinary approach to manage their cancer risk, and various structures have been established across […]
The role of Epstein-Barr virus in nasopharyngeal carcinoma: a case report
Introduction Nasopharyngeal carcinoma (NPC) is classified into three subtypes: keratinizing squamous cell carcinoma (type 1), non-keratinizing squamous cell carcinoma (type 2), and undifferentiated carcinoma (type 3)1,2. The initial symptoms of NPC may be subtle, with an estimated delay of approximately 6 weeks between symptom onset and the first medical evaluation1. Approximately 70% of patients present […]
